Erlotinib intermediates manufacturer
RE-269, also known as ACT-333679, is a long-acting and highly selective prostacyclin receptor agonist. MRE-269, the active form or metabolite of Selexipag (NS-304), is much more selective for the IP receptor than are the prostacyclin analogs beraprost and iloprost, which also have high affinity for the EP(3) receptor.
Product Name: MRE-269, Selexipag Impurity C
CAS:475085-57-5
MW:419.51606
Application:research purpose
Shelf life:2 years
Other Names:ACT-333679
MF:C25H29N3O3
Grade Standard:Pharmaceutical grade
Purity:98% min
Exact Mass:419.221
Molecular Weight:419.516
PSA:75.550
LogP:4.9068
Target:Prostaglandin Receptor
Pathway:GPCR/G Protein
Solubility:DMSO : ≥ 50 mg/mL (119.18 mM)
Supply Ability
300 Gram/Grams per Month
Packaging & Delivery
Packing according to customer's requirements
